Androgen deprivation therapy (ADT) is the main treatment to prolong survival in advance
stage prostate cancer (PCa) but associated resistance leads to the development of terminal
castrate resistant PCa (CRPC). Current research demonstrates that prostate cancer stem
cells (PCSC) play a critical role in the development of treatment resistance and subsequent
disease progression. Despite uncertainty surrounding the origin of these cells, studies
clearly show they are associated with poorer outcomes and that ADT significantly enhances�…